SUMMARY
Yesterday, AGEN presented updated data on its lead candidate, an anti-CTLA-4 at ASCO-GI23
The AGEN ASCO-GI23 presentation included expanded data from the Phase 1a/1b trial expansion cohort in MSS-CRC
Some of the key publicly available slides/data from the presentation is provided below.
Become a free BPIQ.com site member by clicking the link to our free forum POST HERE and get access to deeper data from AGEN's ASCO-GI23 presentation
If you have any trouble signing up to get access to any of these articles, contact support@BPIQ.com
Botensilimab (Boten) is a multifunctional Fc-engineered next generation anti-CTLA-4 antibody that is currently in multiple Phase 2 studies for solid tumors. From prior data it looks more tolerable and possibly more effective than approved anti-CTLA-4 antibodies. See our prior post (CLICK HERE (requires free BPIQ.com account)) for detailed information about Boten and AGEN's double-agent (Boten +balstilimab (AGEN's anti-PD1)) trial in a common form of colorectal cancer, for which we currently don't have effective therapeutic options.
As of this initial post-ASCO-GI23 post, we don't have an official company press release and copy of their slides. And the ASCO-GI23 late-breaker abstract on an initial look, appears to provide the prior SITC 2022 data. However, we see consistent copies of key slides from meeting attendees on social media, as presented below.
FIG. 1 shows the presenter with the study design slide.
FIG. 2 is the updated study design slide. The cutoff for this data was August 29, 2022.
FIG. 3 shows the objective response waterfall plot. Now with 70 subjects enrolled, the Objective Response Rate (ORR) is at 23%, disease control rate at 76%, progression free survival at 4.1 months and the median overall survival has not been reached. As is typical, a response is a tumor reduction of greater than 30%, with stable disease at +/- 30%.
FIG. 4 provides their summary findings and future direction. An interesting point from this slide is the estimated 12 onth overall survival at 63%, much better than current standard of care.
If you want to see more slides and data from the presentation, and more comparison with prior data, sign up for a free BPIQ account today and then CLICK HERE for our deeper AGEN article.
Yorumlar